Storia in 3 fonti

Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone

Raccontata dahealio.commedpagetoday.commorningstar.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mesi fa

Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone

originale

healio.com1 mesi fa

Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard

CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND trial.The…

Leggi questa versione → originale

morningstar.com1 mesi fa

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged…

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously…

Leggi questa versione → originale

Timeline cronologica

1. sabato 30 maggio 2026·healio.com
   

   Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard

   CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the…

2. sabato 30 maggio 2026·medpagetoday.com
   

   Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas

   Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone

3. sabato 30 maggio 2026·morningstar.com
   

   Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival,…

   Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or…

4. lunedì 1 giugno 2026·medpagetoday.com
   

   Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

   Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival